Phibro Animal Health (PAHC) Gains from Sales and Divestitures (2020 - 2026)
Phibro Animal Health (PAHC) recorded quarterly Gains from Sales and Divestitures of $31108.0 in Q1 2026, up 3.69% quarter-over-quarter from $30000.0 in Q2 2025, and up 3.69% on a YoY basis from $30000.0 in Q1 2025.
Phibro Animal Health (PAHC) Gains from Sales and Divestitures (2020 - 2026) Analysis & Trends
Phibro Animal Health's Gains from Sales and Divestitures history runs 3 years deep, the most recent figure standing at $31108.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures rose 3.69% year-over-year to $31108.0; the TTM figure through Mar 2026 stood at $31108.0 (up 3.69% YoY), while the FY2025 annual figure was $30000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $31108.0 for Q1 2026 at Phibro Animal Health, up from $30000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $31108.0 in Q1 2026 to a low of $30000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Phibro Animal Health | 1.26 Bn | 1.19 Bn | 125.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31,108.00 |
| Mar 31, 2026 | 31,108.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Jun 30, 2020 | 50,000.00 |
| Jun 30, 2020 | 50,000.00 |